A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Paricalcitol (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 11 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
- 11 Jul 2018 Planned primary completion date changed from 15 May 2018 to 15 Dec 2019.
- 18 May 2017 Status changed from not yet recruiting to recruiting.